Keke Liang

Shenyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Radiopathomics Signature for Prognosis and Prediction of Chemotherapy Benefit in Unresectable Pancreatic Cancer.

Radiopathomics Signature for Prognosis and Prediction of Chemotherapy Benefit in Unresectable Pancreatic Cancer.

Journal: JCO precision oncology

Published: January 08, 2026

Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcoma.

Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcoma.

Journal: bioRxiv : the preprint server for biology

Published: December 19, 2025

Integrative deep learning analysis of 2D and 3D body composition features for predicting postoperative pancreatic fistula after distal pancreatectomy.

Integrative deep learning analysis of 2D and 3D body composition features for predicting postoperative pancreatic fistula after distal pancreatectomy.

Journal: Annals of medicine

Published: December 04, 2025

Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis.

Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis.

Journal: Communications biology

Published: April 29, 2025

The prognostic value of myosteatosis in pancreatic cancer: A systematic review and meta-analysis.

The prognostic value of myosteatosis in pancreatic cancer: A systematic review and meta-analysis.

Journal: Clinical nutrition (Edinburgh, Scotland)

Published: July 07, 2024

Artificial intelligence to predict T4 stage of pancreatic ductal adenocarcinoma using CT imaging.

Artificial intelligence to predict T4 stage of pancreatic ductal adenocarcinoma using CT imaging.

Journal: Computers in biology and medicine

Published: October 30, 2023

MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling.

MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 27, 2022

18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models.

18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 10, 2022

STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.

STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 26, 2021

Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells.

Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells.

Journal: Cell reports

Published: July 02, 2021

NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.

NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 18, 2021

Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer.

Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer.

Journal: Epigenomics

Published: February 13, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026